The Conversation (0)
BriaCell Therapeutics provided an update on its collaborative and internal research as well as manufacturing activities.
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) provided an update on its collaborative and internal research as well as manufacturing activities.
As quoted in the press release:
Collaborations
The Company has recently initiated a research collaboration with Dr. Maurizio Provenzano, MD, PhD, based at the University of Zurich, Switzerland. Objective of this collaboration is to assess, among others, whether a novel type of immune stimulator predicted to home to sites of malignant disease has additive or synergistic effects in combination with BriaVax™, a whole-cell vaccine for breast cancer.
Click here to read the full press release.
Source: globenewswire.com